Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients
Phase 2
Completed
- Conditions
- Allergy to House Dust MiteAllergic Asthma
- Interventions
- Other: Placebo
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- T-Balance Therapeutics GmbH
- Target Recruit Count
- 42
- Registration Number
- NCT04673591
- Locations
- 🇩🇪
Medaimun GmbH, Frankfurt, Germany
© Copyright 2025. All Rights Reserved by MedPath